Oncotalks hematology videos and news

ASCO 2019 Ana Arance, MD, PhD

Ana Arance, MD, PhD from the Hospital Clínic de Barcelona is commenting on Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507), which was presented at ASCO 2019 in Chicago

Related items

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago
ASCO , Kisqali Channel , Lithuania , Albania , Slovenia
00:03:07
ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago
ASCO , Lithuania , Hungary , Albania
00:06:31
ASCO 2019 Prof. Patrick Neven, MD, PhD

ASCO 2019 Prof. Patrick Neven, MD, PhD

Prof. Patrick Neven, MD, PhD from the UZ Leuven is commenting on his personal top 3 highlights from ASCO 2019 in Chicago1. Saura C. et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol 37, 2019 (suppl; abstr 1002)2. Schmid P. et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 37, 2019 (suppl; abstr 1003)3. Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)
ASCO , Lithuania , Albania
00:03:43